Impact of the Four Pillars on Electrolyte Derangements during State-of-the-Art Therapy for Diabetic Kidney Disease.

The pharmacological management of diabetic kidney disease (DKD) has shifted toward a "four-pillar" approach that offers robust cardiorenal protection. While traditional renin-angiotensin system (RAS) inhibitors carry well-documented electrolyte risks, the distinct electrolyte profiles of novel therapies-sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and non-steroidal mineralocorticoid receptor antagonists (nsMRAs)-warrant a comprehensive understanding. This review examines these drug-induced electrolyte derangements. SGLT2 inhibitors demonstrate a highly favorable safety profile; despite inducing osmotic diuresis, they are notably associated with a reduced risk of hyperkalemia. Similarly, GLP-1 RAs possess an exceptionally low risk of direct renal electrolyte wasting, with imbalances occurring primarily secondary to severe gastrointestinal intolerance. Conversely, nsMRAs, such as finerenone, introduce a mild risk of hyperkalemia, though their unique receptor selectivity significantly diminishes this risk compared to traditional steroidal mineralocorticoid receptor antagonists. Crucially, combining SGLT2 inhibitors and nsMRAs creates a physiological synergy that attenuates hyperkalemic adverse effects while maximizing antiproteinuric benefits. By integrating these complementary mechanisms alongside routine electrolyte monitoring, clinicians can safely sustain these indispensable combination therapies and optimize clinical outcomes in DKD.